Menu

CPTR 2017 Workshop Highlights

CPTR members and TB stakeholders reflect on the breadth and value of CPTR and its annual Workshop.

Perspectives

Tiong Xun Ting on Battling MDR-TB

Challenges to diagnosis and treatment

CPTR Data Sharing Tools: TB-PACTS & ReSeqTB

Info about and how to participate in TB-PACTS and ReSeqTB

CPTR: Workshop 2016 Highlights

Washington DC, April 4-7

News

CPTR 2017 Workshop: Summaries, Slides, and Videos — Day 4

Welcoming Remarks Marco Schito (Critical Path Institute) Marco Schito kicked off the final day of CPTR’s 2017 Workshop by affirming the essential role of diagnostics in effective TB treatment, and contrasting that importance with a lack of corresponding investment in the field, despite such a compelling value proposition. Schito outlined reasons why diagnostic development has […]

May 17, 2017 Drug Development Events RDST Regulatory Science Research Resources Assay Development biomarkers clinical trials Community Engagement CPTR Workshop 2017 diagnostics drug development drug resistance fluroquinolones hollow fiber model next-generation sequencing ReSeq TB ReseqTB TB-PACTS

CPTR 2017 Workshop: Summaries, Slides, and Videos — Day 3

Welcoming Remarks Jim Gallarda (Bill & Melinda Gates Foundation) Jim Gallarda opened the day’s agenda by reminding participants of the importance of collaboration and that silos often act as the largest impediments to progress in global health. Video     Keynote Address: Learning from the Impact of the Drug-Diagnostic Development Strategy in Oncology Jan Trost […]

May 17, 2017 Drug Development Events RDST Regulatory Science Research Resources Assay Development biomarkers clinical trials Community Engagement CPTR Workshop 2017 diagnostics drug development drug resistance fluroquinolones hollow fiber model next-generation sequencing ReSeq TB ReseqTB TB-PACTS

From the Working Groups

Modeling & Simulation Workgroup (M&S-WG) Q4-2015 Update

Working closely with the Data Standards and Integration Workgroup (DSI-WG), the M&S-WG uses aggregated clinical trial data to create robust empirical, mechanistic, and systems biology models and quantitative simulation tools to facilitate TB drug and drug regimen development.

January 22, 2016

Data Standards & Integration Workgroup (DSI-WG) Q4-2015 Update

The DSI-WG provides the information technology (IT) infrastructure to support all CPTR data needs for developing regulatory science tools and methods to enable development of new TB drugs, drug regimens, and diagnostics. Aggregating all relevant data in a secure database for analysis by the CPTR Workgroups and authorized researchers is a key focus for this […]

January 22, 2016

Pre-Clinical and Clinical Sciences Workgroup (PCS-WG) Q4-2015 Update

The PCS-WG is focused on the evidence-based evaluation of translational tools to support effective decision-making and advance new agents from the pre-clinical to clinical development space.  These tools represent innovative approaches to address pre-clinical issues, including pre-clinical in vitro and in vivo efficacy, pre-clinical drug safety, and toxicology, pre-clinical PK/PD analyses involving the use of […]

January 22, 2016
About CPTR

Through partnership, CPTR speeds the development of new and markedly improved drug regimens for tuberculosis.